Yeh Jen Jen, Der Channing J
University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Division of Surgical Oncology, Chapel Hill, NC 27599, USA.
Expert Opin Ther Targets. 2007 May;11(5):673-94. doi: 10.1517/14728222.11.5.673.
Pancreatic cancer is a lethal disease with a 5-year survival rate of 4%. The only opportunity for improved survival continues to be complete surgical resection for those with localized disease. Although chemotherapeutic options are limited for the few patients with resectable disease, this problem is even more magnified in the majority (85%) of patients with unresectable or metastastic disease. Therefore, there is an urgent need for improved therapeutic options. The recent success of inhibitors of signal transduction for the treatment of other cancers supports the need to identify and validate aberrant signaling pathways important for pancreatic tumor growth. This review focuses on the validation of specific signaling networks and the present status of inhibitors of these pathways as therapeutic approaches for pancreatic cancer treatment.
胰腺癌是一种致命疾病，5年生存率为4%。提高生存率的唯一机会仍然是对局限性疾病患者进行完整的手术切除。尽管对于少数可切除疾病的患者，化疗选择有限，但在大多数（85%）不可切除或转移性疾病患者中，这个问题更加突出。因此，迫切需要改进治疗方案。信号转导抑制剂在治疗其他癌症方面最近取得的成功，支持了识别和验证对胰腺肿瘤生长重要的异常信号通路的必要性。本综述重点关注特定信号网络的验证以及这些通路抑制剂作为胰腺癌治疗方法的现状。
